Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 18/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 18/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 18/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 18/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 18/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 18/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046901 | 0.84 | ATM (0.37) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19569149 | 0.80 | KDR (0.56) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3957994 | 0.78 | KDR (0.59) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20752890 | 0.78 | KDR (0.51) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20752888 | 0.78 | KDR (0.51) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20752892 | 0.78 | KDR (0.51) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL535218 | 0.77 | KDR (0.53) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1468261 | 0.76 | KDR (0.68) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19569150 | 0.75 | KDR (0.49) | KDRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13310090 | 0.75 | KDR (0.49) | KDRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-21 | — | — | US | disclosed |
| US-9273013-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-01 | — | — | US | disclosed |
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-11 | — | — | US | disclosed |
| US-8394786-B2 | Quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-1633365-B1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2305687-A1 | Quinazoline derivatives | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178624-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | KDR 2523/4885HDAC3 269/4885HDAC4 843/4885 |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | NR1H3, NR1H2, NCOA3 | KDR 1609/4885HDAC3 48/4885HDAC4 242/4885 |
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | KDR 2393/4885HDAC3 224/4885HDAC4 819/4885 |
| US-20160207938-A1 | QUINAZOLINE DERIVATIVES | NR1H2, NR1H3, NR3C2 | KDR 2189/4885HDAC3 193/4885HDAC4 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.